The firm touted recent Blues coverage decisions for the Afirma thyroid cancer test, and final Medicare coverage policies for the Percepta lung cancer test.
Veracyte said that Quest’s access to half of the physicians and hospitals in the US will provide patients with broader access to the Afirma GEC.
The test is designed to analyze the expression of microRNA biomarkers in indeterminate thyroid fine needle aspirate smears in order to differentiate benign thyroid nodules from malignant ones.
The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.
The new agreement brings Interpace's total insurance coverage for its thyroid assays to approximately 200 million patients.
The state has given its approval for the company to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.
Assessments of the firm's rapid molecular BRAF and EGFR tests by researchers in Italy and South Korea showed high sensitivity and a fast turnaround time.
The test analyzes the expression of 10 microRNAs to classify thyroid nodules as cancerous or benign following indeterminate results from fine-needle aspirate and biopsy samples.
Using a combination of exome sequencing, SNP arrays, and RNA sequencing, researchers found therapeutically informative mutations in most solid tumor cases tested.
Along with known contributors to thyroid cancer, researchers detected mutations that were associated with aggressive cases and metastasis.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.